Otitis media is a set of inflammatory disease that causes infection in the middle ear and is found to be common in children (around three years of age). The disease can be symptomized by sudden onset of ear pain, vomiting, severe earache, fever, and loss of hearing due to build-up of fluid. There are several risk factors for occurrence of otitis media such as, exposure of cigarette smoke, use of pacifier, and have close contact with other infected children. The complications associated with otitis media include mastoiditis (bacterial infection in mastoid bone membrane in skull), damage to inner ear (can be caused by damage to nerves in the ear), and meningitis (infection of membrane covering spinal cord and brain). Yuhan Corporation is in the process of developing YH1177 as a beta lactamase inhibitor for the treatment of otitis media. Lee's Pharmaceutical Limited is developing pazufloxacin mesilate for the treatment of otitis media. Some of the companies having the pipeline of otitis media include Yuhan Corporation, Lee's Pharmaceutical Limited, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.